What to Do When Your Antidepressant Isn’t Working

Roughly a third of people get full relief from their first antidepressant. The rest end up where you might be right now: weeks or months in, still flat, wondering whether to wait it out, raise the dose, or start over with something else.

I’m Dr. Shantanu Baghel, a board-certified psychiatrist treating adults by telehealth across North Carolina. Working through exactly this decision is a large part of what I do in depression treatment. Here’s how I think it through with patients, in the order I actually think it, when antidepressant not working.

How Often the First Antidepressant Falls Short

The best data we have is STAR*D, the largest real-world antidepressant study ever run. It followed thousands of outpatients with depression through up to four sequential treatment steps. About a third reached remission on the first medication. Across all four steps, the cumulative remission rate reached roughly two-thirds (PMID 17074942).

Read that both ways. A first medication that doesn’t work puts you in the majority, and persistence pays: most people who keep working the problem systematically do get better. But each later step helps fewer people than the one before it, so the moves you make after a failed trial should be deliberate, not a shrug and another prescription.

First, Confirm the Trial Was Real

A surprising share of “failed” antidepressant trials were never adequate trials. Before changing anything, I want three answers. Was the dose therapeutic, or did it stay at the starting dose forever? Did the trial run 6 to 8 weeks at that dose? And was the medication actually taken daily, which deserves an honest conversation rather than an assumption.

Time has limits, though. A pooled analysis of over 6,000 patients found that improvement within the first 2 weeks predicts eventual response with high sensitivity (PMID 19254516). If there’s been essentially no movement by week 4 at a real dose, “just give it more time” is usually the wrong advice.

When the trial was underdosed or cut short, the right first move is often to finish it properly. It’s the least glamorous option and it works more often than people expect.

Recheck the Diagnosis Before You Blame the Drug

Antidepressants don’t correct a measurable serotonin deficit. The chemical-imbalance story was always a simplification, so when a medication fails, the useful question is whether it was ever aimed at the right target.

Bipolar spectrum illness is the diagnosis I re-screen for first, because an antidepressant alone can leave it untreated or actively destabilize it. Undiagnosed adult ADHD is another frequent finding; depression layered on untreated ADHD often looks like an antidepressant that “stopped working.” And persistent depressive disorder, the low-grade form that runs for years, responds differently than an acute episode and resets expectations for what one medication can do.

The Medical Contributors Worth Checking

Some depressions don’t lift because something medical is feeding them. Thyroid disease can mimic or worsen depression. Heavy alcohol use can quietly cancel out a working medication. Untreated sleep apnea drags mood down in a way no antidepressant fixes. In men, low testosterone can look exactly like depression, and in women, mood that tracks perimenopause or the postpartum period has a hormonal driver that deserves direct attention. I cover the broader overlap in hormones and mental health and the metabolic side in metabolic psychiatry.

I check labs, sleep, and hormones before the next medication decision. It’s a core part of how I evaluate patients, and you can book a free consultation if you want that fresh set of eyes.

Switch or Augment: How the Decision Actually Works

Once the trial was adequate and the diagnosis holds, there are two main moves: switch to a different medication, or keep the current one and add something to it.

The evidence keeps this honest. In STAR*D, after a failed SSRI, about 1 in 4 patients remitted after switching, and it mattered surprisingly little which medication they switched to (PMID 16554525). In the VA’s VAST-D trial, augmenting with aripiprazole produced modestly higher remission than switching to bupropion (PMID 28697253).

My working rule: a partial response argues for keeping what you’ve gained and augmenting. No response at all, or side effects you can’t live with, argues for switching. The drug you choose matters less than most people think; choosing the right strategy matters more.

Switching Antidepressants Safely

How you switch matters as much as what you switch to. Most switches use a cross-taper: the old medication comes down while the new one comes up, over 2 to 4 weeks depending on the drugs and the doses. Stopping abruptly invites discontinuation symptoms that get mistaken for relapse, a problem I cover in depth in my guide to antidepressant discontinuation.

A few combinations need real caution, and anything involving an MAOI needs a true washout period. This is exactly the kind of transition that should be supervised by the prescriber, with a plan for what to do if the gap weeks get rough.

Augmentation Beyond a Second Antidepressant

Augmentation has a deeper bench than most patients are told. Atypical antipsychotics like aripiprazole carry the strongest modern trial evidence, with metabolic monitoring as the price of admission. Lithium is the oldest augmentation strategy with decades of data behind it, used at lower doses than in bipolar disorder, with blood levels followed. Thyroid hormone (T3) has trial support as well, even with normal thyroid labs.

In men with low or low-normal levels, testosterone is an add-on option worth testing for. A meta-analysis of 27 randomized trials found testosterone treatment reduced depressive symptoms in men, with stronger effects at higher dosing (PMID 30427999). I walk through the evidence and the candidacy questions in testosterone augmentation for depression. Running the psychiatric and hormonal sides in one practice is precisely the point of how mine is built.

When Two Adequate Trials Have Failed

Two adequate trials without remission is the conventional threshold for treatment-resistant depression, and crossing it widens the conversation rather than ending it. Transcranial magnetic stimulation and ECT both have evidence at that stage. My page on treatment-resistant depression care in North Carolina covers what I offer. Some of what comes next I manage directly; for interventional treatments I coordinate with the centers that provide them while staying the physician who knows your whole history. Ketamine will be the exception. I’m preparing to offer IV ketamine and Spravato at my Wilmington office.

The label sounds final. Statistically it isn’t. The diagnostic and medical re-check described above is where I start. If that’s where you are, a free consultation is a reasonable next step.

If You’d Rather Come Off Instead

Some people read all of this and realize their actual goal is to stop. That’s a legitimate decision, and it deserves the same rigor as staying on: a planned taper, a timeline matched to the drug, and supervision for what comes up along the way. My discontinuation guide covers why standard tapers fail and what works better.

Whichever direction you choose, the common thread is having one physician who evaluates properly, knows the evidence, and follows you over time. That’s what working with an online psychiatrist for depression in North Carolina looks like in my practice.

Frequently Asked Questions

How long should I give an antidepressant before deciding it isn’t working?

A fair trial is 6 to 8 weeks at a therapeutic dose. But if there has been essentially no improvement by week 4 at a real dose, the odds of late success drop, and it’s reasonable to reassess sooner rather than later.

Should I increase the dose or switch medications?

If the dose never reached the therapeutic range, bringing the current medication to a full dose often comes first. After an adequate trial, a partial response usually favors augmenting, and no response usually favors switching. The right answer depends on your specific history, which is what the evaluation is for.

Can lab work explain why my antidepressant isn’t working?

Sometimes. Thyroid disease, low testosterone in men, sleep apnea, heavy alcohol use, and metabolic problems can all blunt or mimic a failed antidepressant response. If these were never checked, they belong in the workup before the next medication change.

Does a failed antidepressant mean I have treatment-resistant depression?

No. The conventional threshold is two adequate trials without remission, and many “failed” trials were never adequate in dose or duration. Even past that threshold, there are evidence-based options, which I cover in my article on treatment-resistant depression.

Can you manage a medication change by telehealth in North Carolina?

Yes. Evaluation, lab orders through a lab near you, dose changes, cross-tapers, and follow-up all work over secure video, with prescriptions sent to your local pharmacy. I treat adults anywhere in North Carolina.

This article is for educational purposes only and is not medical advice. It does not create a physician-patient relationship. Never change or stop a psychiatric medication without talking to your prescriber. If you are in crisis or thinking about harming yourself, call or text 988 to reach the Suicide and Crisis Lifeline.

References

1. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917. PMID 17074942.
2. Szegedi A, Jansen WT, van Willigenburg AP, et al. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry. 2009;70(3):344-353. PMID 19254516.
3. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354(12):1231-1242. PMID 16554525.
4. Mohamed S, Johnson GR, Chen P, et al. Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial. JAMA. 2017;318(2):132-145. PMID 28697253.
5. Walther A, Breidenstein J, Miller R. Association of Testosterone Treatment With Alleviation of Depressive Symptoms in Men: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2019;76(1):31-40. PMID 30427999.